Combo showed responses at BLU-945 doses lower than in mono, consistent with additive benefit. The combo safety profile and on-target activity provide rationale for further development in front line.Clinical trial information: NCT04862780.Yasir Y Elamin...
Description BLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can be used for the research of lung cancer including non-small cell lung cancer (NSCLC). Targets EGFR [1] Clinical Trial Information...
EGFR TKI osimertinib. These data showed that these combinations both had enhanced antitumor activity compared with single-agent BLU-945 in anEGFR-positive/T790M/C797S-driven PDX model, which the investigators noted suggest potential for both monotherapy and combination therapy in the clinical setting....
BLU-945 is currently being evaluated in a phase 1/2 clinical trial (NCT 04862780). Experimental Section Compound Synthesis and Characterization All solvents employed were commercially available anhydrous grade, and reagents were used as received unless otherwise noted. Compound purity of all compounds ...
BLU-945 also demonstrated tumor shrinkage in patients from the SYMPHONY trial.#Our findings demonstrate the preclinical and early clinical activity of BLU-945 inEGFRm NSCLC progressing on previous EGFR-TKIs. 展开 关键词: BLU-945 clinical trial design drug resistance EGFR EGFR inhibitors NSCLC ...
BLU-945 alone or in combination with osimertinib demonstrated early signals of clinical activity and was well tolerated in heavily pretreated patients with EGFR-mutant non–small cell lung cancer.
The SYMPHONY trial (BLU-945-1101; NCT04862780) is an international, open-label, first-in-human, phase 1/2 study designed to evaluate safety, tolerability, and antitumor activity of BLU-945 as monotherapy and in combination with osimertinib in patients withEGFRmNSCLC.Methods:Key eligibility ...
BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advancedEGFR-mutant (EGFRm) NSCLC in the phase 1/2 ... YY Elamin,M Nagasaka,E Shum,... - 《Journal of Clinical Oncology》 被引量: 0发表: 2023年 BLU-945, a potent and selective next-gener...